![]() Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | (-)-epigallocatechin 3-gallate | increases expression | ISO | RGD:1318953 | 6480464 | epigallocatechin gallate results in increased expression of ZFP36L2 mRNA | CTD | PMID:16084531 | (-)-epigallocatechin 3-gallate | multiple interactions | ISO | RGD:1318953 | 6480464 | [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ZFP36L2 mRNA | CTD | PMID:22079256 | 17beta-estradiol | affects expression | ISO | RGD:1318954 | 6480464 | Estradiol affects the expression of ZFP36L2 mRNA | CTD | PMID:15598610 | 17beta-estradiol | multiple interactions | ISO | RGD:1318953 | 6480464 | [Estradiol co-treated with TGFB1 protein] results in increased expression of ZFP36L2 mRNA | CTD | PMID:30165855 | 17beta-estradiol | decreases expression | ISO | RGD:1318954 | 6480464 | Estradiol results in decreased expression of ZFP36L2 mRNA | CTD | PMID:19484750 | 17beta-estradiol | decreases expression | ISO | RGD:1318953 | 6480464 | Estradiol results in decreased expression of ZFP36L2 mRNA | CTD | PMID:19167446 | 2,2',4,4'-Tetrabromodiphenyl ether | decreases expression | EXP | | 6480464 | 2 more ... | CTD | PMID:21394737 | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | RGD:1318953 | 6480464 | Tetrachlorodibenzodioxin affects the expression of ZFP36L2 mRNA | CTD | PMID:20106945 | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in increased expression of ZFP36L2 mRNA | CTD | PMID:30621213 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | RGD:1318954 | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of ZFP36L2 mRNA | CTD | PMID:19770486, PMID:26290441 | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | RGD:1318953 | 6480464 | Tetrachlorodibenzodioxin results in increased expression of ZFP36L2 mRNA | CTD | PMID:21632981 | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | EXP | | 6480464 | Tetrachlorodibenzodioxin affects the expression of ZFP36L2 mRNA | CTD | PMID:22298810 | 2,4,6-trinitrobenzenesulfonic acid | increases expression | ISO | RGD:1318954 | 6480464 | Trinitrobenzenesulfonic Acid results in increased expression of ZFP36L2 mRNA | CTD | PMID:17982090 | 2-butoxyethanol | increases expression | ISO | RGD:1318954 | 6480464 | n-butoxyethanol results in increased expression of ZFP36L2 mRNA | CTD | PMID:19812364 | 2-hydroxypropanoic acid | increases expression | ISO | RGD:1318953 | 6480464 | Lactic Acid results in increased expression of ZFP36L2 mRNA | CTD | PMID:30851411 | 3',5'-cyclic AMP | increases abundance | ISO | RGD:1318954 | 6480464 | ZFP36L2 protein mutant form results in increased abundance of Cyclic AMP | CTD | PMID:24830504 | 3,4-methylenedioxymethamphetamine | decreases expression | ISO | RGD:1318954 | 6480464 | N-Methyl-3, 4-methylenedioxyamphetamine results in decreased expression of ZFP36L2 mRNA | CTD | PMID:20188158 | 3-isobutyl-1-methyl-7H-xanthine | multiple interactions | ISO | RGD:1318953 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in increased expression of ZFP36L2 mRNA, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ZFP36L2 mRNA | CTD | PMID:28628672 | 4,4'-diaminodiphenylmethane | increases expression | ISO | RGD:1318954 | 6480464 | 4, 4'-diaminodiphenylmethane results in increased expression of ZFP36L2 mRNA | CTD | PMID:18648102 | 4,4'-sulfonyldiphenol | multiple interactions | ISO | RGD:1318953 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in increased expression of ZFP36L2 mRNA | CTD | PMID:28628672 | 6-propyl-2-thiouracil | increases expression | EXP | | 6480464 | Propylthiouracil results in increased expression of ZFP36L2 mRNA | CTD | PMID:24780913 | 8-bromo-3',5'-cyclic AMP | increases expression | ISO | RGD:1318953 | 6480464 | 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ZFP36L2 mRNA | CTD | PMID:22079614 | benzo[a]pyrene | decreases expression | ISO | RGD:1318954 | 6480464 | Benzo(a)pyrene results in decreased expression of ZFP36L2 mRNA | CTD | PMID:27195522 | benzo[a]pyrene | decreases expression | ISO | RGD:1318953 | 6480464 | Benzo(a)pyrene results in decreased expression of ZFP36L2 mRNA | CTD | PMID:20106945, PMID:21632981 | bisphenol A | affects expression | EXP | | 6480464 | bisphenol A affects the expression of ZFP36L2 mRNA | CTD | PMID:25181051 | bisphenol A | affects methylation | ISO | RGD:1318954 | 6480464 | bisphenol A affects the methylation of ZFP36L2 promoter | CTD | PMID:27334623 | bisphenol A | increases methylation | EXP | | 6480464 | bisphenol A results in increased methylation of ZFP36L2 gene | CTD | PMID:28505145 | bisphenol F | multiple interactions | ISO | RGD:1318953 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ZFP36L2 mRNA | CTD | PMID:28628672 | buta-1,3-diene | decreases expression | ISO | RGD:1318954 | 6480464 | 1, 3-butadiene results in decreased expression of ZFP36L2 mRNA | CTD | PMID:29038090 | C60 fullerene | increases expression | EXP | | 6480464 | fullerene C60 results in increased expression of ZFP36L2 mRNA | CTD | PMID:19167457 | cadmium atom | increases expression | ISO | RGD:1318953 | 6480464 | Cadmium results in increased expression of ZFP36L2 mRNA | CTD | PMID:24376830 | carbamazepine | affects expression | ISO | RGD:1318953 | 6480464 | Carbamazepine affects the expression of ZFP36L2 mRNA | CTD | PMID:25979313 | chlorpyrifos | increases expression | ISO | RGD:1318954 | 6480464 | Chlorpyrifos results in increased expression of ZFP36L2 mRNA | CTD | PMID:30621213 | chlorpyrifos | decreases expression | EXP | | 6480464 | Chlorpyrifos results in decreased expression of ZFP36L2 mRNA | CTD | PMID:27905518 | chlorpyrifos | decreases expression | ISO | RGD:1318954 | 6480464 | Chlorpyrifos results in decreased expression of ZFP36L2 mRNA | CTD | PMID:27905518 | choline | multiple interactions | ISO | RGD:1318954 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of ZFP36L2 gene | CTD | PMID:20938992 | cisplatin | multiple interactions | ISO | RGD:1318953 | 6480464 | [Piroxicam co-treated with Cisplatin] results in increased expression of ZFP36L2 mRNA | CTD | PMID:21858171 | cisplatin | decreases expression | ISO | RGD:1318953 | 6480464 | Cisplatin results in decreased expression of ZFP36L2 mRNA | CTD | PMID:27594783 | cisplatin | decreases expression | ISO | RGD:1318954 | 6480464 | Cisplatin results in decreased expression of ZFP36L2 mRNA | CTD | PMID:21151649 | cisplatin | decreases expression | EXP | | 6480464 | Cisplatin results in decreased expression of ZFP36L2 mRNA | CTD | PMID:22023808 | cisplatin | affects response to substance | ISO | RGD:1318953 | 6480464 | ZFP36L2 protein affects the susceptibility to Cisplatin | CTD | PMID:16217747 | clofibrate | decreases expression | ISO | RGD:1318954 | 6480464 | Clofibrate results in decreased expression of ZFP36L2 mRNA | CTD | PMID:17585979 | cobalt dichloride | decreases expression | ISO | RGD:1318953 | 6480464 | cobaltous chloride results in decreased expression of ZFP36L2 mRNA | CTD | PMID:19320972, PMID:19376846 | Colforsin dapropate hydrochloride | decreases expression | ISO | RGD:1318953 | 6480464 | Colforsin results in decreased expression of ZFP36L2 mRNA | CTD | PMID:15967414 | crotonaldehyde | decreases expression | ISO | RGD:1318953 | 6480464 | 2-butenal results in decreased expression of ZFP36L2 mRNA | CTD | PMID:20471460 | CU-O LINKAGE | decreases expression | ISO | RGD:1318953 | 6480464 | cupric oxide results in decreased expression of ZFP36L2 mRNA | CTD | PMID:22077320 | cyclosporin A | decreases expression | ISO | RGD:1318953 | 6480464 | Cyclosporine results in decreased expression of ZFP36L2 mRNA | CTD | PMID:20106945, PMID:25562108 | cypermethrin | increases expression | ISO | RGD:1318954 | 6480464 | cypermethrin results in increased expression of ZFP36L2 mRNA | CTD | PMID:29020013 | dexamethasone | increases expression | ISO | RGD:1318953 | 6480464 | Dexamethasone results in increased expression of ZFP36L2 mRNA | CTD | PMID:25047013 | dexamethasone | multiple interactions | ISO | RGD:1318953 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in increased expression of ZFP36L2 mRNA, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ZFP36L2 mRNA | CTD | PMID:28628672 | dibutyl phthalate | increases expression | EXP | | 6480464 | Dibutyl Phthalate results in increased expression of ZFP36L2 mRNA | CTD | PMID:21266533 | dibutyl phthalate | decreases expression | EXP | | 6480464 | Dibutyl Phthalate results in decreased expression of ZFP36L2 mRNA | CTD | PMID:24893172 | dicrotophos | increases expression | ISO | RGD:1318953 | 6480464 | dicrotophos results in increased expression of ZFP36L2 mRNA | CTD | PMID:28302478 | dioxygen | increases expression | ISO | RGD:1318954 | 6480464 | Oxygen deficiency results in increased expression of ZFP36L2 mRNA | CTD | PMID:24205000 | disodium selenite | increases expression | ISO | RGD:1318953 | 6480464 | Sodium Selenite results in increased expression of ZFP36L2 mRNA | CTD | PMID:18175754 | diuron | decreases expression | EXP | | 6480464 | Diuron results in decreased expression of ZFP36L2 mRNA | CTD | PMID:21551480 | dorsomorphin | multiple interactions | ISO | RGD:1318953 | 6480464 | [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | doxorubicin | decreases response to substance | ISO | RGD:1318953 | 6480464 | ZFP36L2 mRNA results in decreased susceptibility to Doxorubicin | CTD | PMID:16322897 | doxorubicin | affects response to substance | ISO | RGD:1318953 | 6480464 | ZFP36L2 protein affects the susceptibility to Doxorubicin | CTD | PMID:16217747 | endosulfan | decreases expression | EXP | | 6480464 | Endosulfan results in decreased expression of ZFP36L2 mRNA | CTD | PMID:29391264 | ethanol | multiple interactions | ISO | RGD:1318953 | 6480464 | [[Gasoline co-treated with Ethanol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ZFP36L2 mRNA | CTD | PMID:29432896 | Ethylenethiourea | decreases expression | EXP | | 6480464 | Ethylenethiourea results in decreased expression of ZFP36L2 mRNA | CTD | PMID:27905518 | Ethylenethiourea | decreases expression | ISO | RGD:1318954 | 6480464 | Ethylenethiourea results in decreased expression of ZFP36L2 mRNA | CTD | PMID:27905518 | fenamidone | increases expression | ISO | RGD:1318954 | 6480464 | fenamidone results in increased expression of ZFP36L2 mRNA | CTD | PMID:27029645 | folic acid | multiple interactions | ISO | RGD:1318954 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of ZFP36L2 gene | CTD | PMID:20938992 | gentamycin | increases expression | EXP | | 6480464 | Gentamicins results in increased expression of ZFP36L2 mRNA | CTD | PMID:22061828 | hydrogen peroxide | affects expression | ISO | RGD:1318953 | 6480464 | Hydrogen Peroxide affects the expression of ZFP36L2 mRNA | CTD | PMID:20044591 | indometacin | multiple interactions | ISO | RGD:1318953 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in increased expression of ZFP36L2 mRNA, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ZFP36L2 mRNA | CTD | PMID:28628672 | irinotecan | decreases expression | ISO | RGD:1318953 | 6480464 | Irinotecan metabolite results in decreased expression of ZFP36L2 mRNA, Irinotecan results in decreased expression of ZFP36L2 mRNA | CTD | PMID:15956246 | L-methionine | multiple interactions | ISO | RGD:1318954 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of ZFP36L2 gene | CTD | PMID:20938992 | lead diacetate | increases expression | ISO | RGD:1318954 | 6480464 | lead acetate results in increased expression of ZFP36L2 mRNA | CTD | PMID:21829687 | leflunomide | increases expression | ISO | RGD:1318953 | 6480464 | leflunomide results in increased expression of ZFP36L2 mRNA | CTD | PMID:28988120 | menadione | affects expression | ISO | RGD:1318953 | 6480464 | Vitamin K 3 affects the expression of ZFP36L2 mRNA | CTD | PMID:20044591 | methylmercury chloride | increases expression | ISO | RGD:1318953 | 6480464 | methylmercuric chloride results in increased expression of ZFP36L2 mRNA | CTD | PMID:28001369 | N-acetyl-L-cysteine | increases expression | ISO | RGD:1318953 | 6480464 | Acetylcysteine results in increased expression of ZFP36L2 mRNA | CTD | PMID:16084531 | nickel sulfate | increases expression | ISO | RGD:1318953 | 6480464 | nickel sulfate results in increased expression of ZFP36L2 mRNA | CTD | PMID:18651567 | orphenadrine | affects expression | EXP | | 6480464 | Orphenadrine affects the expression of ZFP36L2 mRNA | CTD | PMID:23665939 | paclitaxel | affects response to substance | ISO | RGD:1318953 | 6480464 | ZFP36L2 protein affects the susceptibility to Paclitaxel | CTD | PMID:16217747 | panobinostat | multiple interactions | ISO | RGD:1318953 | 6480464 | [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZFP36L2 mRNA | CTD | PMID:27188386 | panobinostat | increases expression | ISO | RGD:1318953 | 6480464 | panobinostat results in increased expression of ZFP36L2 mRNA | CTD | PMID:26272509 | paracetamol | decreases expression | ISO | RGD:1318953 | 6480464 | Acetaminophen results in decreased expression of ZFP36L2 mRNA | CTD | PMID:21420995 | paracetamol | increases expression | ISO | RGD:1318953 | 6480464 | Acetaminophen results in increased expression of ZFP36L2 mRNA | CTD | PMID:26690555 | phenobarbital | affects expression | ISO | RGD:1318954 | 6480464 | Phenobarbital affects the expression of ZFP36L2 mRNA | CTD | PMID:23091169 | pirinixic acid | multiple interactions | ISO | RGD:1318953 | 6480464 | [pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of ZFP36L2 mRNA | CTD | PMID:19710929 | pirinixic acid | increases expression | ISO | RGD:1318954 | 6480464 | pirinixic acid results in increased expression of ZFP36L2 mRNA | CTD | PMID:18301758, PMID:18445702 | piroxicam | multiple interactions | ISO | RGD:1318953 | 6480464 | [Piroxicam co-treated with Cisplatin] results in increased expression of ZFP36L2 mRNA | CTD | PMID:21858171 | potassium chromate | increases expression | ISO | RGD:1318953 | 6480464 | potassium chromate(VI) results in increased expression of ZFP36L2 mRNA | CTD | PMID:22079256 | potassium chromate | multiple interactions | ISO | RGD:1318953 | 6480464 | [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ZFP36L2 mRNA | CTD | PMID:22079256 | rac-lactic acid | increases expression | ISO | RGD:1318953 | 6480464 | Lactic Acid results in increased expression of ZFP36L2 mRNA | CTD | PMID:30851411 | rotenone | increases expression | EXP | | 6480464 | Rotenone results in increased expression of ZFP36L2 mRNA | CTD | PMID:28374803 | SB 431542 | multiple interactions | ISO | RGD:1318953 | 6480464 | [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | silicon dioxide | decreases expression | ISO | RGD:1318953 | 6480464 | Silicon Dioxide analog results in decreased expression of ZFP36L2 mRNA | CTD | PMID:25895662 | silver atom | decreases expression | ISO | RGD:1318953 | 6480464 | Silver results in decreased expression of ZFP36L2 mRNA | CTD | PMID:26014281 | silver(0) | decreases expression | ISO | RGD:1318953 | 6480464 | Silver results in decreased expression of ZFP36L2 mRNA | CTD | PMID:26014281 | sodium arsenite | decreases expression | ISO | RGD:1318953 | 6480464 | sodium arsenite results in decreased expression of ZFP36L2 mRNA | CTD | PMID:25879800 | Soman | increases expression | EXP | | 6480464 | Soman results in increased expression of ZFP36L2 mRNA | CTD | PMID:19281266 | tamoxifen | affects expression | ISO | RGD:1318954 | 6480464 | Tamoxifen affects the expression of ZFP36L2 mRNA | CTD | PMID:20937368 | tetrachloroethene | increases expression | ISO | RGD:1318954 | 6480464 | Tetrachloroethylene results in increased expression of ZFP36L2 mRNA | CTD | PMID:28973375 | thioacetamide | increases expression | EXP | | 6480464 | Thioacetamide results in increased expression of ZFP36L2 mRNA | CTD | PMID:23411599 | thioacetamide | increases methylation | EXP | | 6480464 | Thioacetamide results in increased methylation of ZFP36L2 promoter | CTD | PMID:27914986 | titanium dioxide | decreases expression | ISO | RGD:1318954 | 6480464 | titanium dioxide results in decreased expression of ZFP36L2 mRNA | CTD | PMID:29264374 | torcetrapib | increases expression | ISO | RGD:1318953 | 6480464 | torcetrapib results in increased expression of ZFP36L2 mRNA | CTD | PMID:23228038 | trichostatin A | decreases expression | ISO | RGD:1318953 | 6480464 | trichostatin A results in decreased expression of ZFP36L2 mRNA | CTD | PMID:24935251 | trichostatin A | affects expression | ISO | RGD:1318953 | 6480464 | trichostatin A affects the expression of ZFP36L2 mRNA | CTD | PMID:28542535 | trichostatin A | multiple interactions | ISO | RGD:1318953 | 6480464 | [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZFP36L2 mRNA | CTD | PMID:27188386 | trichostatin A | increases expression | ISO | RGD:1318953 | 6480464 | trichostatin A results in increased expression of ZFP36L2 mRNA | CTD | PMID:24935251, PMID:26272509 | troglitazone | decreases expression | ISO | RGD:1318954 | 6480464 | troglitazone results in decreased expression of ZFP36L2 mRNA | CTD | PMID:28973697 | tungsten | decreases expression | ISO | RGD:1318954 | 6480464 | Tungsten results in decreased expression of ZFP36L2 mRNA | CTD | PMID:30912803 | valdecoxib | increases expression | EXP | | 6480464 | valdecoxib results in increased expression of ZFP36L2 mRNA | CTD | PMID:24136188 | valproic acid | affects expression | ISO | RGD:1318954 | 6480464 | Valproic Acid affects the expression of ZFP36L2 mRNA | CTD | PMID:17292431 | valproic acid | multiple interactions | ISO | RGD:1318953 | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZFP36L2 mRNA | CTD | PMID:27188386 | valproic acid | increases expression | ISO | RGD:1318953 | 6480464 | Valproic Acid results in increased expression of ZFP36L2 mRNA | CTD | PMID:24383497 more ... | valproic acid | affects expression | ISO | RGD:1318953 | 6480464 | Valproic Acid affects the expression of ZFP36L2 mRNA | CTD | PMID:25979313 | valproic acid | decreases expression | ISO | RGD:1318953 | 6480464 | Valproic Acid results in decreased expression of ZFP36L2 mRNA | CTD | PMID:24935251, PMID:29154799 | vincaleukoblastine | affects response to substance | ISO | RGD:1318953 | 6480464 | ZFP36L2 protein affects the susceptibility to Vinblastine | CTD | PMID:16217747 | zoledronic acid | increases expression | ISO | RGD:1318953 | 6480464 | zoledronic acid results in increased expression of ZFP36L2 mRNA | CTD | PMID:20977926 | |

Biological Process
Cellular Component
Molecular Function